Plant ID: NPO15147
Plant Latin Name: Ficus simplicissima
Taxonomy Genus: Ficus
Taxonomy Family: Moraceae
NCBI TaxonomyDB:
1822162
Plant-of-the-World-Online:
853709-1
Nepal; Bangladesh; Myanmar; Indonesia; India; Cambodia; Vietnam; China; Laos; Thailand
DRD3; | |
ALPL; | |
SRC; IGF1R; PTK2; AXL; MAPK1; ALK; KDR; | |
CA2; CA14; | |
NFKB1; | |
LMNA; |
Cytochrome P450 Enzymes: | CYP2A6; |
---|
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Small molecule receptor (family A GPCR) | DRD3 | Dopamine D3 receptor | P35462 | CHEMBL234 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 3.025E-08 | 1.098E-04 | IGF1R, KDR, PTK2, SRC |
MF | GO:0060089; molecular transducer activity | GO:0004714; transmembrane receptor protein tyrosine kinase activity | 9.401E-08 | 2.559E-04 | ALK, AXL, IGF1R, KDR |
BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 1.727E-07 | 3.133E-04 | AXL, KDR, PTK2, SRC |
BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 1.151E-06 | 9.279E-04 | AXL, KDR, MAPK1, NFKB1, SRC |
BP | GO:0022610; biological adhesion | GO:0051893; regulation of focal adhesion assembly | 7.356E-06 | 3.601E-03 | KDR, PTK2, SRC |
BP | GO:0040011; locomotion | GO:0030335; positive regulation of cell migration | 1.035E-05 | 4.421E-03 | IGF1R, KDR, MAPK1, PTK2, SRC |
BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.202E-05 | 4.901E-03 | CA2, DRD3, KDR, SRC |
BP | GO:0050896; response to stimulus | GO:0010035; response to inorganic substance | 1.283E-05 | 4.901E-03 | AXL, CA2, KDR, MAPK1, SRC |
BP | GO:0009987; cellular process | GO:0060159; regulation of dopamine receptor signaling pathway | 2.188E-05 | 7.111E-03 | ALK, DRD3 |
BP | GO:0009987; cellular process | GO:0038127; ERBB signaling pathway | 2.691E-05 | 8.254E-03 | MAPK1, PTK2, SRC |
BP | GO:0050896; response to stimulus | GO:0038166; angiotensin-activated signaling pathway | 3.206E-05 | 9.564E-03 | CA2, SRC |
MF | GO:0005488; binding | GO:0005524; ATP binding | 3.201E-05 | 9.564E-03 | ALK, AXL, IGF1R, KDR, MAPK1, PTK2, SRC |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 7.661E-08 | 8.449E-06 | SRC, KDR, MAPK1, PTK2 |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.906E-07 | 8.449E-06 | SRC, KDR, MAPK1, PTK2, IGF1R |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 1.860E-07 | 8.449E-06 | SRC, KDR, MAPK1, PTK2, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 2.469E-06 | 8.208E-05 | KDR, MAPK1, PTK2, NFKB1, IGF1R |
09150 Organismal Systems | 09151 Immune system | hsa04062 | Chemokine signaling pathway | 6.885E-06 | 1.831E-04 | SRC, MAPK1, NFKB1, PTK2 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 1.109E-05 | 2.209E-04 | SRC, KDR, MAPK1, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 1.480E-05 | 2.286E-04 | KDR, MAPK1, NFKB1, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 1.583E-05 | 2.286E-04 | SRC, MAPK1, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05131 | Shigellosis | 1.163E-05 | 2.209E-04 | SRC, MAPK1, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 2.993E-05 | 3.317E-04 | MAPK1, NFKB1, IGF1R |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 1.719E-05 | 2.286E-04 | SRC, MAPK1, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04012 | ErbB signaling pathway | 2.795E-05 | 3.317E-04 | SRC, MAPK1, PTK2 |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.307E-04 | 1.023E-03 | MAPK1, NFKB1, PTK2, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 4.633E-05 | 4.740E-04 | MAPK1, NFKB1, IGF1R |
09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 1.155E-04 | 1.023E-03 | LMNA, MAPK1, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 1.308E-04 | 1.023E-03 | SRC, MAPK1, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 3.554E-04 | 2.327E-03 | SRC, MAPK1, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05152 | Tuberculosis | 2.347E-04 | 1.698E-03 | SRC, MAPK1, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 2.426E-04 | 1.698E-03 | NFKB1, PTK2, IGF1R |
09140 Cellular Processes | 09142 Cell motility | hsa04810 | Regulation of actin cytoskeleton | 4.030E-04 | 2.437E-03 | SRC, MAPK1, PTK2 |
09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 7.030E-04 | 3.634E-03 | SRC, KDR, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 6.858E-04 | 3.634E-03 | ALK, MAPK1 |
09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 7.104E-04 | 3.634E-03 | MAPK1, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 9.229E-04 | 4.363E-03 | MAPK1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 3.673E-04 | 2.327E-03 | SRC, MAPK1 |
09150 Organismal Systems | 09156 Nervous system | hsa04730 | Long-term depression | 7.869E-04 | 3.876E-03 | MAPK1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 9.514E-04 | 4.363E-03 | MAPK1, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 1.100E-03 | 4.547E-03 | MAPK1, IGF1R |
09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 1.010E-03 | 4.476E-03 | SRC, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 1.162E-03 | 4.547E-03 | MAPK1, NFKB1 |
09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 1.162E-03 | 4.547E-03 | MAPK1, NFKB1 |
09150 Organismal Systems | 09151 Immune system | hsa04621 | NOD-like receptor signaling pathway | 7.104E-04 | 3.634E-03 | MAPK1, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05140 | Leishmaniasis | 1.162E-03 | 4.547E-03 | MAPK1, NFKB1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04912 | GnRH signaling pathway | 1.798E-03 | 5.979E-03 | SRC, MAPK1 |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 2.209E-03 | 6.528E-03 | MAPK1, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 1.608E-03 | 5.629E-03 | NFKB1, PTK2 |
09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 2.081E-03 | 6.528E-03 | MAPK1, IGF1R |
09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 1.917E-03 | 6.219E-03 | NFKB1, IGF1R |
09160 Human Diseases | 09167 Infectious diseases | hsa05100 | Bacterial invasion of epithelial cells | 1.326E-03 | 4.897E-03 | SRC, PTK2 |
09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 2.123E-03 | 6.528E-03 | SRC, MAPK1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05133 | Pertussis | 1.226E-03 | 4.660E-03 | MAPK1, NFKB1 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 1.683E-03 | 5.739E-03 | SRC, MAPK1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05146 | Amoebiasis | 2.166E-03 | 6.528E-03 | NFKB1, PTK2 |
09160 Human Diseases | 09167 Infectious diseases | hsa05132 | Salmonella infection | 1.608E-03 | 5.629E-03 | MAPK1, NFKB1 |
09150 Organismal Systems | 09151 Immune system | hsa04620 | Toll-like receptor signaling pathway | 2.429E-03 | 6.731E-03 | MAPK1, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 2.613E-03 | 7.091E-03 | MAPK1, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05142 | Chagas disease (American trypanosomiasis) | 2.340E-03 | 6.621E-03 | MAPK1, NFKB1 |
09150 Organismal Systems | 09151 Immune system | hsa04660 | T cell receptor signaling pathway | 2.340E-03 | 6.621E-03 | MAPK1, NFKB1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 2.999E-03 | 7.777E-03 | SRC, MAPK1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05145 | Toxoplasmosis | 2.999E-03 | 7.777E-03 | MAPK1, NFKB1 |
09150 Organismal Systems | 09151 Immune system | hsa04611 | Platelet activation | 3.201E-03 | 7.866E-03 | SRC, MAPK1 |
09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 3.099E-03 | 7.777E-03 | MAPK1, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 3.099E-03 | 7.777E-03 | MAPK1, NFKB1 |
09140 Cellular Processes | 09143 Cell growth and death | hsa04114 | Oocyte meiosis | 3.253E-03 | 7.866E-03 | MAPK1, IGF1R |
09150 Organismal Systems | 09158 Development | hsa04380 | Osteoclast differentiation | 3.735E-03 | 8.402E-03 | MAPK1, NFKB1 |
09150 Organismal Systems | 09158 Development | hsa04360 | Axon guidance | 3.463E-03 | 8.156E-03 | MAPK1, PTK2 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 3.790E-03 | 8.402E-03 | MAPK1, IGF1R |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 4.307E-03 | 9.391E-03 | MAPK1, IGF1R |
09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 3.790E-03 | 8.402E-03 | MAPK1, NFKB1 |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 6.151E-05 | 5.844E-04 | CA2, CA14 |
09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 3.495E-03 | 8.156E-03 | CYP2A6 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
C00-D49: Neoplasms | AML | NA | KDR; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | PTK2; IGF1R; KDR; MAPK1; SRC; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; SRC; |
C00-D49: Neoplasms | Colon cancer | C50 | ALPL; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD3; |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
NA: NA | Edema | NA | CA2; |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | DRD3; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD3; |
C00-D49: Neoplasms | Breast cancer | C50 | IGF1R; KDR; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
C00-D49: Neoplasms | Mesothelioma | C45 | PTK2; |
C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | IGF1R; |
C00-D49: Neoplasms | Cancer | C00-C96 | PTK2; IGF1R; KDR; NFKB1; MAPK1; SRC; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; |
C00-D49: Neoplasms | Glioma | C71 | KDR; |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | DRD3; |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | IGF1R; KDR; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | DRD3; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | IGF1R; KDR; AXL; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD3; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD3; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | DRD3; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |